Telix Pharmaceuticals (TLX) investor relations material

Commercial and operational highlights

• Achieved significant commercial growth, expanding into 17 countries and launching new products in the prostate cancer space, with approvals in the US, Europe, UK, Brazil, and filings in China and Japan.

• Delivered 2.9 million doses across all segments in the past year, with 150,000 Illuccix and Gazelix doses in the US, leveraging a vertically integrated supply chain and nuclear pharmacy network.

• Revenue guidance for the full year is $800–$820 million, with expectations to surpass $1 billion in the next few years, driven by multi-product and regional expansion.

• Workforce grew from 350 to nearly 1,200, reflecting organizational maturation and increased operational capability.

• RLS Radiopharmacy acquisition and new cyclotron facilities enhance U.S. production and distribution.

Strategic vision and business model

• Focused on radiopharmaceutical therapeutics and precision medicine, leveraging an integrated theranostic approach and global manufacturing excellence.

• Commercial stage with a diversified portfolio of late- and early-stage assets, supported by specialist commercial teams.

• Growth strategy centers on expanding product offerings, geographies, and indications, with robust manufacturing and supply chain infrastructure.

• Strategic focus on reinvesting commercial revenue into pipeline and infrastructure through 2027, prioritizing long-term value creation over near-term earnings.

• The company is positioned as a self-funded biotech, reinvesting earnings to build pipeline and infrastructure, with a focus on long-term growth and innovation.

Product and pipeline highlights

• Two FDA-approved PSMA imaging agents (Illuccix, Gozellix) with broad international reach and reimbursement secured.

• Multiple late-stage (phase 3) therapeutic programs are underway, including TLX-591 for prostate cancer, CA-9, and a glioblastoma agent, with imminent data readouts and global recruitment.

• NDA and BLA resubmissions for Pixclara and Zircaix are progressing, with anticipated US launches in 2026, and plans for global registrations.

• Next-generation assets (TLX592-Tx, TLX252-Tx) entering first-in-human trials, with additional candidates for bone pain and pan-cancer indications.

• Ongoing innovation in alpha-emitting therapies and biologic-centric formats, with first-in-human studies for DLL3 and alpha v beta 6 expected by year-end.